Healthcare share price target

After a strong showing in Q1FY19 due to the base effect and currency tailwinds, we expect some consolidation in Q2 financials due to 1) higher base and 2) cost pressure that can be attributed to supply constraints from China and higher crude prices. These two factors are likely to dilute strong currency tailwinds. The I-direct healthcare universe is expected to register 10% YoY growth. Domestic formulations are likely to grow 5.6% YoY (select pack) due to high base owing to channel restoration in Q2FY18 post GST implementation. US revenues (select pack) are expected to grow 8%...

ICICI Securities Ltd. | Retail Equity Research Course correction drive after turbulent FY16... FY16 turned out to be a demanding fiscal for pharma players after a near...

Indian pharma market (IPM) grew 3.5%YoY to INR82b in April 2016, much lower than 6.5%YoY reported in April 2016. Growth was largely impacted by external factors like FDC ban and NLEM list....

Indian pharma market (IPM) grew 6.4%YoY to INR72b in March 2016, much lower than the last month growth of 12.0%YoY. Moving annual (MAT) growth for March 2016 stood at 12.6% YoY, primarily...